PF-Atlas › Clinical Trials › NCT01890265
Evaluate the Safety and Efficacy of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
Pamrevlumab · Phase 2
Registry ID
NCT01890265
Phase
Phase 2
Status
Completed
Drug / intervention
Pamrevlumab
Sponsor
Kyntra Bio
Start
2013-07-30
About this trial
Pamrevlumab is evaluated in NCT01890265, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Kyntra Bio. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01890265 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.